Acrivon Therapeutics (ACRV) Stock Forecast, Price Target & Predictions
ACRV Stock Forecast
Acrivon Therapeutics stock forecast is as follows: an average price target of $21.50 (represents a 141.30% upside from ACRV’s last price of $8.91) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
ACRV Price Target
The average price target for Acrivon Therapeutics (ACRV) is $21.50 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $17.00. This represents a potential 141.30% upside from ACRV's last price of $8.91.
ACRV Analyst Ratings
According to 7 Wall Street analysts, Acrivon Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ACRV stock is 0 'Strong Buy' (0.00%), 7 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Acrivon Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 13, 2024 | Matthew Biegler | Oppenheimer | $18.00 | $7.26 | 147.93% | 102.02% |
| May 14, 2024 | Matthew Biegler | Oppenheimer | $21.00 | $8.36 | 151.20% | 135.69% |
| May 14, 2024 | Emily Bodnar | H.C. Wainwright | $22.00 | $8.35 | 163.63% | 146.91% |
| May 14, 2024 | Etzer Darout | BMO Capital | $25.00 | $8.51 | 193.77% | 180.58% |
| Apr 25, 2024 | Joseph Catanzaro | Piper Sandler | $30.00 | $9.20 | 226.09% | 236.70% |
| Apr 25, 2024 | Silvan Tuerkcan | JMP Securities | $17.00 | $9.50 | 78.95% | 90.80% |
| Mar 28, 2024 | Emily Bodnar | H.C. Wainwright | $20.00 | $7.18 | 178.36% | 124.47% |
| Dec 12, 2022 | - | Jefferies | $17.00 | $12.50 | 36.00% | 90.80% |
| Dec 11, 2022 | Joseph Catanzaro | Piper Sandler | $25.00 | $12.50 | 100.00% | 180.58% |
The latest Acrivon Therapeutics stock forecast, released on Aug 13, 2024 by Matthew Biegler from Oppenheimer, set a price target of $18.00, which represents a 147.93% increase from the stock price at the time of the forecast ($7.26), and a 102.02% increase from ACRV last price ($8.91).
Acrivon Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 7 |
| Avg Price Target | - | $18.00 | $21.86 |
| Last Closing Price | $8.91 | $8.91 | $8.91 |
| Upside/Downside | -100.00% | 102.02% | 145.34% |
In the current month, the average price target of Acrivon Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Acrivon Therapeutics's last price of $8.91. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 14, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Aug 13, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| May 14, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| May 14, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 14, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Apr 25, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Apr 25, 2024 | JMP Securities | Outperform | Outperform | Hold |
| Mar 28, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Mar 28, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Dec 12, 2022 | Cowen & Co. | - | Outperform | Initialise |
Acrivon Therapeutics's last stock rating was published by BMO Capital on Aug 14, 2024. The company gave ACRV a "Outperform" rating, the same as its previous rate.
Acrivon Therapeutics Financial Forecast
Acrivon Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | $2.20M | - | - | - | - | - | - |
| High Forecast | $2.20M | - | - | - | - | - | - |
| Low Forecast | $2.20M | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Acrivon Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ACRV's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Acrivon Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict ACRV's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Acrivon Therapeutics's previous annual EBITDA (undefined) of $NaN.
Acrivon Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-26.38M | $-26.50M | $-25.17M | $-22.88M | $-22.07M | $-20.87M | $-21.77M |
| High Forecast | $-26.38M | $-26.50M | $-25.17M | $-22.88M | $-22.07M | $-19.38M | $-21.77M |
| Low Forecast | $-26.38M | $-26.50M | $-25.17M | $-22.88M | $-22.07M | $-22.36M | $-21.77M |
| Surprise % | - | - | - | - | - | - | - |
Acrivon Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ACRV's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Acrivon Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Acrivon Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ACRV last annual SG&A of $NaN (undefined).
Acrivon Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.73 | $-0.73 | $-0.70 | $-0.63 | $-0.61 | $-0.58 | $-0.60 |
| High Forecast | $-0.73 | $-0.73 | $-0.70 | $-0.63 | $-0.61 | $-0.54 | $-0.60 |
| Low Forecast | $-0.73 | $-0.73 | $-0.70 | $-0.63 | $-0.61 | $-0.62 | $-0.60 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Acrivon Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ACRV previous annual EPS of $NaN (undefined).
Acrivon Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PMVP | PMV Pharmaceuticals | $1.51 | $24.75 | 1539.07% | Buy |
| ANTX | AN2 Therapeutics | $1.04 | $8.75 | 741.35% | Buy |
| AVTE | Aerovate Therapeutics | $1.90 | $13.00 | 584.21% | Hold |
| MOLN | Molecular Partners | $5.22 | $29.00 | 455.56% | Buy |
| OPT | Opthea | $3.15 | $14.00 | 344.44% | Buy |
| ANEB | Anebulo Pharmaceuticals | $2.08 | $6.00 | 188.46% | Buy |
| MLYS | Mineralys Therapeutics | $11.76 | $30.00 | 155.10% | Buy |
| RZLT | Rezolute | $5.25 | $13.00 | 147.62% | Buy |
| ACRV | Acrivon Therapeutics | $8.91 | $21.50 | 141.30% | Buy |
| ADAG | Adagene | $3.49 | $5.00 | 43.27% | Buy |
| ANAB | AnaptysBio | $40.33 | $36.33 | -9.92% | Buy |
ACRV Forecast FAQ
Is Acrivon Therapeutics a good buy?
Yes, according to 7 Wall Street analysts, Acrivon Therapeutics (ACRV) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 100.00% of ACRV's total ratings.
What is ACRV's price target?
Acrivon Therapeutics (ACRV) average price target is $21.5 with a range of $17 to $30, implying a 141.30% from its last price of $8.91. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Acrivon Therapeutics stock go up soon?
According to Wall Street analysts' prediction for ACRV stock, the company can go up by 141.30% (from the last price of $8.91 to the average price target of $21.5), up by 236.70% based on the highest stock price target, and up by 90.80% based on the lowest stock price target.
Can Acrivon Therapeutics stock reach $13?
ACRV's average twelve months analyst stock price target of $21.5 supports the claim that Acrivon Therapeutics can reach $13 in the near future.
What are Acrivon Therapeutics's analysts' financial forecasts?
Acrivon Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-64.72M (high $-63.23M, low $-66.211M), average SG&A $0 (high $0, low $0), and average EPS is $-1.791 (high $-1.75, low $-1.832). ACRV's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $2.2M (high $2.2M, low $2.2M), average EBITDA is $0 (high $0, low $0), average net income is $-101M (high $-101M, low $-101M), average SG&A $0 (high $0, low $0), and average EPS is $-2.793 (high $-2.793, low $-2.793).